MHRA Statement on Pathways Clinical Trial Safety

MHRA Guidance & Safety

Published February 27th, 2026

Detected February 28th, 2026

Summary

The MHRA has issued a statement regarding the Pathways clinical trial, emphasizing participant safety. As a precaution, Professor Jacob George has been recused from further involvement due to social media posts made prior to his appointment.

View original document View source feed page

What changed

The MHRA has issued a statement concerning the Pathways clinical trial, highlighting its commitment to participant safety and ongoing scientific dialogue with trial sponsors. A key development is the recusal of Professor Jacob George from further involvement in the trial as a precautionary measure, following the identification of social media posts made before his appointment.

This action indicates a heightened level of scrutiny on clinical trial personnel and potential conflicts of interest. While the statement reassures that the MHRA's experts are working constructively with King's College London, it signals that regulatory bodies are taking a proactive stance on issues that could compromise trial integrity or participant well-being. Companies involved in clinical trials should ensure robust vetting processes for key personnel and be prepared for active regulatory engagement on safety and ethical considerations.

Source document (simplified)

News story

MHRA statement on Pathways clinical trial

As with all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants.

From: Medicines and Healthcare products Regulatory Agency Published 27 February 2026

An MHRA spokesperson said:

“With all clinical trials, the MHRA’s top priority is the safety and wellbeing of the trial participants. As part of that commitment, complex clinical trials are kept continuously under review and the MHRA maintains an active scientific dialogue with trial sponsors.

“The MHRA has world-class medical, scientific, and regulatory experts who work as a multidisciplinary team to provide evidence-based decisions on clinical trials. These experts will continue to meet with King’s College London to work through the next steps constructively.

“Following the identification of social media posts made prior to his appointment, Professor Jacob George is recused from further involvement on the Pathways clinical trial as a precaution.”